Literature DB >> 31442069

Surgical Lung Biopsy and Cryobiopsy in Fibrosing Interstitial Lung Diseases: One Swallow Does Not Make a Summer.

Elisabeth Bendstrup1, Sissel Kronborg-White1, Line Bille Madsen1, Torben R Rasmussen1, Birgitte Folkersen1, Nina Voldby1, Janne Møller1, Venerino Poletti1.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31442069      PMCID: PMC6812444          DOI: 10.1164/rccm.201904-0744LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


× No keyword cloud information.
To the Editor: In a recent issue of the Journal, Romagnoli and colleagues presented a small prospective study comparing transbronchial lung cryobiopsy (TBLC) with surgical lung biopsy (SLB) (1). First, the authors must be complimented for the achievement of obtaining biopsies by sequentially using two different methods in the same patients, especially considering the risk of hemorrhage and acute exacerbation of an underlying fibrosing interstitial lung disease (ILD). Previous studies have shown excellent diagnostic yields with TBLC, but data regarding the accuracy of this approach have been lacking, and it is in the light of this gap that the present study is important. Regrettably, the study questions the accuracy of TBLC, as a comparison of TBLC and SLB seems to show discordant pathology findings, thus challenging the use of TBLC for diagnosing ILD. However, the present results need to be carefully evaluated. First of all, only a small number of patients were recruited from the two centers, with only 62 patients referred for a multidisciplinary evaluation for ILD over a period of 28 months, and only 21 patients submitted to biopsy and included in the study with, at best, 11 patients at each ILD center. It was previously reported that there is a learning curve with respect to TBLC complications, and this is also true for the quality of the biopsies (2). There are no data regarding the total quantity of TBLC procedures performed in the two centers or the number of procedures performed per bronchoscopist. Training in the field of TBLC seems to be important and should be reported (2, 3). Aside from being described as “good to excellent” in most cases, the biopsies were not defined in terms of quality (the authors judged 2 biopsies as poor, 3 as average, 13 as good, 3 as very good, and 3 as excellent). However, the criteria for making this judgment are not specified. Also, the localization of the biopsy site (i.e., central/peribronchial or peripheral) is not reported, and neither is the presence of pleura in the biopsy, a sign that shows that the biopsy is from the peripheral compartments of the lung (4). The pneumothorax rate of 9.5% was low, which also indicates that biopsies were taken from more central lung compartments. The mean size of the TBLC was 4.7 mm (range, 2.5–8.0 mm; median size, 7 mm; interquartile range, 5–8 mm). A learning curve in TBLC has been reported not only with respect to complications but also with respect to the quality and size of the biopsies. In a previous study, Almeida and colleagues assessed 100 TBLCs performed in patients with suspected diffuse lung disease (2). When they compared the first 50 TBLCs with the next 50 TBLCs, they found that the length and area of the biopsies were smaller and the diagnostic yield was lower in the first group, and all parameters improved when the bronchoscopists gained more experience. In their study, Almeida and colleagues reported a median length of 5.0 mm in the first 50 biopsies and 6.0 mm in the next 50 biopsies. Romagnoli and colleagues reported a level of agreement between external blinded versus local pathology reports as fair to moderate, with κ values of 0.22–0.51. The κ values for individual pathologists are not presented, and as noted above for bronchoscopy, there may be a learning curve for pathologic evaluations of cryobiopsies. In support of this, previous studies (which included the same external pathologist as in the present study) reported κ values between 0.59 and 0.61 (5, 6). With regard to the agreement between the pathologic diagnosis based on the two types of specimens and the final diagnosis at the second multidisciplinary assessment or the final treatment (Table 2 and Table E3 in the online supplement of Reference 1), there is no statistically significant difference by conventional standards between the two types of specimens in terms of performance when evaluated by a chi-square test or Fisher’s exact test on simple 2 × 2 tables, even though there is trend in favor of SLB. This emphasizes the need for further research into this important subject before any conclusions can be made. The TBLCs were compared with SLBs as the gold standard. However, the accuracy of SLB has never been proven, and previous studies (7) have clearly shown that SLBs can also provide discordant results when performed in different lobes; thus, the perception of SLB as the gold standard requires careful consideration. The study by Romagnoli and colleagues certainly indicates that more research into the accuracy of TBLC is warranted, but their results cannot stand alone and should not discourage the continued use of TBLC in interstitial lung disease.
  6 in total

1.  Report Standardization in Transbronchial Lung Cryobiopsy.

Authors:  Claudia Ravaglia; Giulio Rossi; Sara Tomassetti; Alessandra Dubini; Sara Piciucchi; Marco Chilosi; Alberto Cavazza; Elisabeth Bendstrup; Sissel Brix Kronborg-White; Birgitte Folkersen; Sara Colella; Line Bille Madsen; Venerino Poletti
Journal:  Arch Pathol Lab Med       Date:  2019-04       Impact factor: 5.534

2.  Histopathologic variability in usual and nonspecific interstitial pneumonias.

Authors:  K R Flaherty; W D Travis; T V Colby; G B Toews; E A Kazerooni; B H Gross; A Jain; R L Strawderman; A Flint; J P Lynch; F J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2001-11-01       Impact factor: 21.405

3.  Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases.

Authors:  Micaela Romagnoli; Thomas V Colby; Jean-Philippe Berthet; Anne Sophie Gamez; Jean-Pierre Mallet; Isabelle Serre; Alessandra Cancellieri; Alberto Cavazza; Laurence Solovei; Andrea Dell'Amore; Giampiero Dolci; Aldo Guerrieri; Paul Reynaud; Sébastien Bommart; Maurizio Zompatori; Giorgia Dalpiaz; Stefano Nava; Rocco Trisolini; Carey M Suehs; Isabelle Vachier; Nicolas Molinari; Arnaud Bourdin
Journal:  Am J Respir Crit Care Med       Date:  2019-05-15       Impact factor: 21.405

4.  Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis.

Authors:  Sara Tomassetti; Athol U Wells; Ulrich Costabel; Alberto Cavazza; Thomas V Colby; Giulio Rossi; Nicola Sverzellati; Angelo Carloni; Elisa Carretta; Matteo Buccioli; Paola Tantalocco; Claudia Ravaglia; Christian Gurioli; Alessandra Dubini; Sara Piciucchi; Jay H Ryu; Venerino Poletti
Journal:  Am J Respir Crit Care Med       Date:  2016-04-01       Impact factor: 21.405

5.  Introduction of cryobiopsies in the diagnostics of interstitial lung diseases - experiences in a referral center.

Authors:  Sissel Kronborg-White; Birgitte Folkersen; Torben Riis Rasmussen; Nina Voldby; Line Bille Madsen; Finn Rasmussen; Venerino Poletti; Elisabeth Bendstrup
Journal:  Eur Clin Respir J       Date:  2017-01-09

6.  Transbronchial biopsy is useful in predicting UIP pattern.

Authors:  Sara Tomassetti; Alberto Cavazza; Thomas V Colby; Jay H Ryu; Oriana Nanni; E Scarpi; Paola Tantalocco; Matteo Buccioli; Alessandra Dubini; Sara Piciucchi; Claudia Ravaglia; Christian Gurioli; Gian Luca Casoni; Carlo Gurioli; Micaela Romagnoli; Venerino Poletti
Journal:  Respir Res       Date:  2012-10-29
  6 in total
  1 in total

1.  Lung Cryobiopsy for the Diagnosis of Interstitial Lung Diseases: A Series Contribution to a Debated Procedure.

Authors:  Sergio Harari; Francesca Cereda; Federico Pane; Alberto Cavazza; Nikolaos Papanikolaou; Giuseppe Pelosi; Monica Scarioni; Elisabetta Uslenghi; Maurizio Zompatori; Antonella Caminati
Journal:  Medicina (Kaunas)       Date:  2019-09-19       Impact factor: 2.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.